

**AMENDMENTS TO THE CLAIMS**

1-99. (Canceled).

100. (Previously Presented) ~~An~~ The oligonucleotide of claim 44, wherein the oligonucleotide has having the following structure:  
5' T\*C\_G\*T\*C\_G\*T\*T\*T\*T\*G\*A\*C\_G\*T\*T\*T\*T\*G\*T\*C\_G\*T\*T 3' (SEQ ID NO: 313),  
wherein \* refers to the presence of a stabilized internucleotide linkage, and wherein \_ refers to the presence of a phosphodiester internucleotide linkage and wherein the oligonucleotide has a length of 16-40 nucleotides.

101. (New) The oligonucleotide of claim 100, wherein the oligonucleotide consists essentially of 5' T\*C\_G\*T\*C\_G\*T\*T\*T\*T\*G\*A\*C\_G\*T\*T\*T\*T\*G\*T\*C\_G\*T\*T 3'.

102. (New) The oligonucleotide of claim 100, wherein the oligonucleotide consists of 5' T\*C\_G\*T\*C\_G\*T\*T\*T\*T\*G\*A\*C\_G\*T\*T\*T\*T\*G\*T\*C\_G\*T\*T 3'.

103. (New) The oligonucleotide of claim 100, formulated in a composition, further comprising a carrier.

104. (New) The oligonucleotide of claim 100, wherein the stabilized internucleotide linkage is a phosphorothioate internucleotide linkage.

105. (New) An oligonucleotide having the following structure: 5' T\*C\_G\*T\*C\_G\*T\*T\*T\*T\*G\*A\*C\_G\*T\*T\*T\*T\*G\*T\*C\_G\*T\*T 3' (SEQ ID NO: 313) wherein each \* refers to a phosphorothioate internucleotide linkage and each \_ refers to a phosphodiester internucleotide linkage, and wherein the oligonucleotide is 24 nucleotides in length.

106. (New) A pharmaceutical composition comprising an oligonucleotide as defined in claim 100 and a pharmaceutically acceptable carrier.

107. (New) A pharmaceutical composition comprising an oligonucleotide as defined in claim 105 and a pharmaceutically acceptable carrier.